Landmark trials with PCSK9 inhibitors
PCSK9: Outcomes and trials in clinical perspective
This video is part of an educational series of four lectures focussed on PCSK9: Outcomes and trials in clinical perspective. In this module, Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.
Video navigation menu
- FOURIER: benefit of evolocumab in patients with stable ASCVD 00:48
- ODYSSEY OUTCOMES: results of alirocumab in patients post-ACS 03:12
- Primary efficacy in prespecified LDL subgroups 05:30
- ODYSSEY OUTCOMES: Safety results 06:37
- Results in patients with ACS and diabetes 07:18
This educational video is the second part of a series called "PCSK9: Outcomes and trials in clinical perspective" that are aimed to give cardiologists in secondary care and other healthcare professionals with an interest in treating patients with cardiovascular disease a well-balanced expert view on the current state of the art about the impact of PCSK9 inhibition on lipids and cardiovascular risk
This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Other topics covered in this series
Other lectures part of this educational series are:
- Identifying patients for PCSK9 therapy - Prof. Kees Hovingh, MD, Amsterdam University Medical Center , The Netherlands
- PCSK9 inhibitors: How do they work? - Prof. John Chapman, Pierre and Marie Curie University, Paris, France
- Guidelines and the role of non-statin therapies for high risk ASCVD patients - Prof. Wouter Jukema, MD, Leiden University Medical Center, The Netherlands
Ph. Gabriel Steg is a cardiologist in the Hôpital Bichat, Paris, France. He is also Professor at the National Heart and Lung Institute, Imperial College, London, UK.
This course is applied for online CME accreditation at EBAC (European Board for Accreitation in Cardiology). Once accredited the CME programme will be available in our CME section
This educational series is funded by an unrestricted educational grant provided by Sanofi-Regeneron.